BioNTech SE
22UA
Rang in Aktien
#1015
BioNTech SE is a biotechnology firm dedicated to the research, development, and... BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.
Aktienkurs
$92.64
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$23.27B
Veränderung (1 Tag)
-1.88%
Veränderung (1 Jahr)
-11.43%
Land
DE
Handel BioNTech SE (22UA)
Kategorie
Healthcare
Operative Marge für BioNTech SE (22UA)
Operative Marge zum October 2026 TTM: -64.63%
Laut den neuesten Finanzberichten und dem Aktienkurs von BioNTech SE beträgt die aktuelle operative Marge (TTM) -64.63%. Am Ende des Jahres 2023 lag die operative Marge bei 18.08%.
Historie der operativen Marge von BioNTech SE von 2016 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | -64.63% | 35.29% |
| 2024 | -47.77% | -364.21% |
| 2023 | 18.08% | -75.24% |
| 2022 | 73.03% | -9.32% |
| 2021 | 80.54% | -571.27% |
| 2020 | -17.09% | -89.78% |
| 2019 | -167.16% | 296.02% |
| 2018 | -42.21% | -57.57% |
| 2017 | -99.48% | 0.00% |
| 2016 | 0.00% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -100.60% |
US
|
|
| -149.01% | -97.69% |
US
|
|
| 25.57% | -100.40% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.45% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.